Genexis Biotech, a Vadodara-based bio-manufacturing company focused on animal-origin-free recombinant proteins, has raised ₹4 crore in its seed funding round led by GVFL. The round also saw participation from Benzai10.
The funds raised will be used to expand its bioreactor capacity, build downstream processing infrastructure, and launch a new line of smart proteins and recombinant peptidase enzymes. It will also use the funds to strengthen quality control, regulatory compliance, and expand its sales and distribution channels.
Founded in 2019 by Vipul Kumar and Jitendra Wagh, Genexis Biotech is a bio-manufacturing company developing high-quality, animal-origin-free proteins using recombinant technology and precision fermentation. With a robust in-house R&D and ISO-compliant infrastructure, the company serves key sectors like biopharma, regenerative medicine, cell culture media, and cultivated meat.
In the past 12 months, Genexis has developed a range of recombinant growth factors, peptidases, and cell culture reagents. It has established strategic partnerships with pharmaceutical companies, biotech startups, and research laboratories.
Genexis Biotech recently introduced recombinant peptidases such as amino peptidase and enterokinase, and is preparing to launch recombinant transferrin and albumin. Genexis also signed an MoU with the Gujarat government for scaling up recombinant protein manufacturing and showcased its portfolio at Global Bio-India 2024. It has secured multiple clients and has received orders for alternative protein formulation projects.
In the next phase of growth, Genexis Biotech aims to enter the regulated biotech export market, form strategic collaborations with Contract Development and Manufacturing Organisations (CDMOs), academic labs and biopharma companies. Its plans also include developing encapsulated growth factor formulations for the cosmetics industry.
Vipul Kumar, Director at Genexis Biotech, said, “At Genexis Biotech, we are building India’s deep-tech backbone for animal-origin-free protein production. The seed round marks a key milestone in our journey and will accelerate our path to scale, enabling sustainable innovation across healthcare, food, and bio-industrial sectors.”
Mihir Joshi, Managing Director of GVFL, said, “Genexis is solving a critical gap in India’s biotech value chain by enabling high-quality, animal-origin-free protein production at scale. The company’s R&D strength, infrastructure, and early traction position it well to serve a growing demand across biopharma, food-tech, and life sciences. We are pleased to support Genexis in this transformative journey.”
